Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.